Pharma sustainability: Amgen debuts $750M ‘green bond,’ Merck initiates ESG goal review
A pair of environment, social and governance (ESG) news reports this week point out the emphasis pharma is putting on sustainability efforts thanks to increasing demands from investors and consumers.
Amgen debuted its first-ever green funding — a $750 million bond earmarked for environmental projects including green buildings, renewable energy and clean transportation — on Tuesday, while Merck dialed up investors for a first-ever briefing on its ESG efforts on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
